ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors
LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic.
ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated.
Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “AXL is a novel and ideal target for an ADC approach, as it is overexpressed in many solid tumor types. We look forward to exploring the effect of ADCT-601 on patients with selected advanced solid tumors who have failed or are intolerant to any established therapy. With five ADCs in eight ongoing clinical trials for multiple indications, we believe our highly targeted therapies have the potential to meaningfully improve outcomes for patients with solid tumors and hematological cancers.”
The open-label, multicenter, single-arm trial will include a Phase Ia dose-escalation part followed by a Phase Ib dose-expansion part. The dose-escalation part is designed to determine the maximum tolerated dose of ADCT-601. The identified dose will be evaluated in the dose-expansion part. Approximately 75 patients will be enrolled in the trial. For more information, please visit www.clinicaltrials.gov (identifier NCT03700294).
ADCT-601 is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human AXL, conjugated using GlycoConnect™ technology to a linker with a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell where enzymes release the PBD-based warhead. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and ultimately killing the cancer cell. ADCT-601 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors (NCT03700294).
About ADC Therapeutics
ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has five PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II, in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.
Dr. Chris Martin
Chief Executive Officer
Tel.: +41 (0) 21 653 0200
EU Media Contact
Tel: +41 (0) 43 268 3231
USA Media Contact
Tel.: +1 908-591-2839
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Media Advisory: Bombardier to Report its First Quarter 2019 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 223.4.2019 22:54:00 CEST | Pressemelding
MONTRÉAL, April 23, 2019 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2019 and hold its annual meeting of shareholders at the Grand Quay (former Alexandra Pier) located in Montréal’s Old Port on Thursday, May 2, 2019. Quarterly conference call On May 2 at 8:00 a.m., EDT, Bombardier’s management will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter of 2019. Please find below the dial-in information for the call: In English: 514 394 9320 or 1 866 240 8954 (toll-free in North America) +800 6578 9868 (overseas calls) In French: 514 394 9316 or (with translation) 1 888 791 1368 (toll-free in North America) +800 6578 9868 (overseas calls) Annual meeting of shareholders WHERE: Grand Quay, 200 de la Commune Street West, Montréal, Québec, H2Y 4B2 WHEN: Thursday, May 2, 2019 Media registration: 9:30 a.m. - 10:15 a.m. Eastern Daylight Time (EDT) Op
Patton Enhances Cloud Orchestration Service with OA&M Messaging23.4.2019 20:05:00 CEST | Pressemelding
Expanding its virtualized NMS with alerts and notifications sent to mobile teams, Patton reduces operational expense and complexity for service providers SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., April 23, 2019 (GLOBE NEWSWIRE) -- Patton Electronics—creator of SmartNode virtual VoIP CPE and CopperLink Ethernet and power-over-Ethernet extenders—has enhanced its revolutionary Patton Cloud virtualized edge-orchestration service by adding new alerts and notifications capabilities, the company announced today. WATCH the VIDEO TUTORIAL Patton Cloud Alerts and Notifications Added alerting and notification capabilities augment the Patton Cloud with fault and performance-monitoring tools for service-quality assurance, as well as device and service management. The Patton cloud already provides automated onboarding and provisioning as part of its full-service, life-cycle orchestration solution. Now, element status, statistics, faults, alerts, and alarms can all be delivered to techn
Continued Growth for INVNT Following Client Wins, An Expanded Offering, New Offices and Fresh Talent23.4.2019 15:20:00 CEST | Pressemelding
NEW YORK, NY, April 23, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, achieved a number of milestones in 2018, a move that saw its revenues reach over $54 million, exceeding forecasts and representing a 30% increase on the previous year. With a number of impressive new clients and continued expansion in the works, the agency is targeting $62 million in revenue for 2019. INVNT secured new clients including Microsoft, Facebook, Pfizer, Xero, TEDxSydney, New Relic and Mary Kay last year. They grew many accounts from local to global, a move that now sees INVNTrs deliver campaigns for clients across the globe. INVNT also exceeded existing clients’ expectations in 2018, delivering compelling live brand storytelling™ moments for the likes of General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway. Scott Cullather, CEO, INVNT explains: “Our tremendous growth is due to a combination of our team’s ability to develop compelling live brand stories that are
Always Powered by Passion: Meizu 16s Flagship Smartphone Unveiled, Snapdragon 855 and 48MP OIS Dual Camera23.4.2019 15:00:00 CEST | Pressemelding
Zhuhai, April 23, 2019 (GLOBE NEWSWIRE) -- Zhuhai, 23rd April 2019 -- Meizu Technology Co., Ltd (Meizu) has officially introduced its latest flagship 16s and will be available for sale in China on 28th April starting at 3198 RMB. The signature Meizu Design brings a sense of elegance to the phone. Powered by Qualcomm Snapdragon 855, the 16s features a 48MP + OIS Dual Camera, making it the best device to use for everyday shots. The latest flagship 16s is a testament to the 16 years’ experience in phone making of Meizu. The company has spared no effort with 100% dedication in producing premium phone for quality-seeking users, despite the size of the target market. 16s is a product that reflects ‘100% efforts for 1% selected Products’, Meizu strives for excellence with passion. Meizu 16s comes in Pearl White, Carbon Black, and Phantom Blue, of which 6+128G, 8+128G and 8+256G will be respectively priced at 3198 RMB, 3498 RMB and 3998 RMB, and will be available on Meizu official website for
iGrafx Announces Cohesive RPA Accelerator Solution23.4.2019 14:48:00 CEST | Pressemelding
Combines Core Capabilities from iGrafx, myInvenio, Servicetrace, UiPath and BP3 Global Dallas, TX, April 23, 2019 (GLOBE NEWSWIRE) -- Today at the iNNOVATE 2019 conference, iGrafx unveiled the industry’s first end-to-end RPA Accelerator solution, enabling enterprises to identify, assess, prioritize, execute and govern robotic process automation (RPA) projects. The turnkey package includes a new version of the iGrafx Platform, along with process mining from myInvenio, RPA bots from either UiPath or Servicetrace and professional services from BP3. For the first time ever, Center of Excellence leaders can access the combined, best-of-breed capabilities from a single source for a single price. “Our customers tell us that they have a huge challenge understanding what to optimize and automate in order to achieve real digital transformation,” said Ryan Tognazzini, CEO at iGrafx. This is a challenge that is also iterated again and again by industry experts. In a recent Forrester report, Rob Ko
MJBizDaily Introduces MJBizDaily European Cannabis Symposium, Copenhagen, Denmark, May 623.4.2019 11:00:00 CEST | Pressemelding
DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- The producers of America’s oldest and largest cannabis trade show, Marijuana Business Conference & Expo (MJBizCon), introduce MJBizDaily’s European Cannabis Symposium in Denmark, Copenhagen. MJBizDaily’s European Cannabis Symposium will take place on Monday, May 6 at the Scandic Copenhagen Hotel in Copenhagen, Denmark. Leaders in the business, research and legislation of Europe’s medical marijuana and hemp market will gather for an intensive one-day conference offering educational sessions on the latest in tech, scientific research, and potential impacts on global markets. Table top exhibitors and an opening cocktail reception on Sunday, May 5 will also offer invaluable networking opportunities. “Regulated, normalized cannabis programs are just now starting to come into their own across Europe. As those government, industry and scientific ties continue to strengthen across the continent, the time is right to provide an in-person platform for e